In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein-2 identifies a pocket important in modulating sodium channel slow inactivation

In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein-2 identifies a pocket important in modulating sodium channel slow inactivation

Item

http://www.wikidata.org/entity/Q34055749

Q34055749

about

Development of lacosamide for the treatment of partial-onset seizures Specific binding of lacosamide to collapsin response mediator protein 2 (CRMP2) and direct impairment of its canonical function: implications for the therapeutic potential of lacosamide Collapsin response mediator protein 2: high-resolution crystal structure sheds light on small-molecule binding, post-translational modifications, and conformational flexibility.Differential regulation of collapsin response mediator protein 2 (CRMP2) phosphorylation by GSK3ß and CDK5 following traumatic brain injury.The functionalized amino acid (S)-Lacosamide subverts CRMP2-mediated tubulin polymerization to prevent constitutive and activity-dependent increase in neurite outgrowth Substituted N-(biphenyl-4'-yl)methyl (R)-2-acetamido-3-methoxypropionamides: potent anticonvulsants that affect frequency (use) dependence and slow inactivation of sodium channels.Prevention of posttraumatic axon sprouting by blocking collapsin response mediator protein 2-mediated neurite outgrowth and tubulin polymerization.Development and characterization of novel derivatives of the antiepileptic drug lacosamide that exhibit far greater enhancement in slow inactivation of voltage-gated sodium channels.Merging Structural Motifs of Functionalized Amino Acids and α-Aminoamides Results in Novel Anticonvulsant Compounds with Significant Effects on Slow and Fast Inactivation of Voltage-gated Sodium Channels and in the Treatment of Neuropathic Pain.Chimeric agents derived from the functionalized amino acid, lacosamide, and the α-aminoamide, safinamide: evaluation of their inhibitory actions on voltage-gated sodium channels, and antiseizure and antinociception activities and comparison with lac VOLTAGE-GATED CALCIUM CHANNELS ARE NOT AFFECTED BY THE NOVEL ANTI-EPILEPTIC DRUG LACOSAMIDE.Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca²⁺ channel complex Chimeric derivatives of functionalized amino acids and α-aminoamides: compounds with anticonvulsant activity in seizure models and inhibitory actions on central, peripheral, and cardiac isoforms of voltage-gated sodium channels.Safety of lacosamide in children with refractory partial epilepsy.Post-translational modifications of voltage-gated sodium channels in chronic pain syndromes Inhibition of transmitter release and attenuation of anti-retroviral-associated and tibial nerve injury-related painful peripheral neuropathy by novel synthetic Ca2+ channel peptides.Identification of the benzyloxyphenyl pharmacophore: a structural unit that promotes sodium channel slow inactivation Opening Pandora's jar: a primer on the putative roles of CRMP2 in a panoply of neurodegenerative, sensory and motor neuron, and central disorders.Discovery of lacosamide affinity bait agents that exhibit potent voltage-gated sodium channel blocking properties.SUMOylation alters CRMP2 regulation of calcium influx in sensory neurons.CRMP2 protein SUMOylation modulates NaV1.7 channel trafficking.mTORC1-dependent translation of collapsin response mediator protein-2 drives neuroadaptations underlying excessive alcohol-drinking behaviors.Novel medications for epilepsy.Ion channel drug discovery: challenges and future directions.Lacosamide for the treatment of partial-onset seizures.Neurological perspectives on voltage-gated sodium channels.Advances in epilepsy treatment: lacosamide pharmacokinetic profile.CRMPs: critical molecules for neurite morphogenesis and neuropsychiatric diseases.Role of Sodium Channels in Epilepsy.Sustained relief of ongoing experimental neuropathic pain by a CRMP2 peptide aptamer with low abuse potential.Drug binding assays do not reveal specific binding of lacosamide to collapsin response mediator protein 2 (CRMP-2).Analgesic ineffectiveness of lacosamide after spinal nerve ligation and its sodium channel activity in injured neurons.Distribution of lacosamide in the rat brain assessed by in vitro slice technique.(S)-Lacosamide Binding to Collapsin Response Mediator Protein 2 (CRMP2) Regulates CaV2.2 Activity by Subverting Its Phosphorylation by Cdk5.Mapping protein interactions of sodium channel NaV1.7 using epitope-tagged gene-targeted mice.Cdk5-mediated phosphorylation of CRMP-2 enhances its interaction with CaV2.2.Lanthionine ketimine ethyl ester partially rescues neurodevelopmental defects in unc-33 (DPYSL2/CRMP2) mutants.

P2860

Q24629140-590309B4-44EF-4B09-8E33-FDC7D61486BE Q27014744-E209711E-0F5F-46E1-B994-CD2B0B4EF8C4 Q30396999-42C8B644-56C7-4712-AEF4-B72FF3362C58 Q33671879-1CBD1206-423C-4FF2-8E75-83086EE48B96 Q33944532-282676F2-9C75-4D05-96A7-96FE5A9F3F80 Q33951922-3BA03900-6600-4246-8D95-AB009297488B Q34203586-0A80F875-F62F-49CB-9072-379CB9B81150 Q34865999-D63A9F99-480A-4FC8-A7A4-35BAB6F81835 Q35099293-B3B95763-D364-4C65-812F-E8D80C088F0A Q35212961-99C257F9-2D67-4C08-80E3-B179E311E01D Q35227081-2E4E4E65-74A5-49FA-B4DD-0218655E0CA2 Q35561043-4F5395D2-CCC1-461C-8CAE-23B4F529D189 Q35706539-50EF2DF0-02C3-4739-8BA5-81279206B70C Q36162002-3DB38B18-6F09-4C7B-AB31-AEF0259CF96A Q36249467-50D8FB7A-47DA-4B93-A6D7-E5BD150F59D1 Q36318896-3BDD663F-02EC-45C6-9537-D17E594D89FC Q36479712-FCE937F9-10BF-4AD5-866C-1847753CF98C Q36517220-B0E3AD0A-4E2C-48D7-9A7F-24C7A0272605 Q36709110-9D2DBE5B-1E95-454D-888B-CD8F64068316 Q37009051-568170E2-70E1-4348-AC57-2E3FDE6CABF2 Q37112626-04ADAD85-5FC5-4B4B-86B5-E9A4A4112327 Q37395961-2B916F9B-9F91-4E42-90EB-ABBBBD17FAF9 Q37950518-0262F828-AD6C-41C4-85E2-C8AB47BB5E2A Q37998135-92810FCB-99B3-4653-9AEF-00144F0F9904 Q38014885-F582C4BC-261C-420F-970F-87AE26C3C0E6 Q38042001-FA499D46-A29D-4ABD-8619-85D654E769D7 Q38244248-828A72A1-0531-4FEF-B9A5-411BA6FB7AAC Q38528533-257E9318-DE8B-4B58-A5D2-19DD41489441 Q38825019-94D4AFE6-D94D-4536-BCA4-9A3547545C8E Q39168504-7609D085-324B-4A41-BFF0-7A2325E2BE0B Q39336259-4033435E-3B90-42CB-AE12-D002E9F8D8FB Q45363773-775B0EC2-C88F-4806-B7CC-7FD88082AD59 Q47668140-164C3C49-D5F6-4FA9-8B2A-4A686B96BEBA Q48205863-A2B89046-4133-477C-8753-766587FFD946 Q48240918-3A79F35C-84D5-41B0-AF33-8195B862071B Q48357626-88BFA6CC-3970-42ED-B688-E24A21842D46 Q50477710-07A58D70-BBD9-4D35-B51C-09D73258C8FB

P2860

In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein-2 identifies a pocket important in modulating sodium channel slow inactivation

Item

http://www.wikidata.org/entity/Q34055749

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu